FDA 483 - Seqirus Inc

Seqirus Inc. in Holly Springs, North Carolina, was cited for significant deficiencies in its influenza vaccine manufacturing processes. The inspection revealed inadequate control procedures for detecting particulates in pre-filled syringes, insufficient testing of critical raw materials like Squalene, and failures in sterility testing with unassigned root causes. These issues indicate a lack of robust quality control and process validation.